EX VIVO EXPANSION OF CANINE DENDRITIC CELLS FROM CD34+ BONE MARROW PROGENITOR CELLS1
Hans Hägglund(Uppsala University Hospital), Richard A. Nash(Colorado Blood Cancer Institute), George Mathioudakis(Fred Hutch Cancer Center), Peter F. Moore(University of California, Davis), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Peter A. McSweeney(Mesoblast (United States)), M. John Gass(Fred Hutch Cancer Center), George E. Sale, George E. Georges(Northwestern University)
Cited by 28
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k